-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical Network News on August 16 A few days ago, Hunan Jiudian Pharmaceutical entered the administrative examination and approval stage with the imitation of 4 types of flurbiprofen gel plaster, which is expected to become the first domestic plaster to be reviewed
.
According to data from Meinnet.
com, flurbiprofen gel plaster will have a terminal sales of more than 1 billion yuan in China's public medical institutions in 2020, making it the best-selling plaster
.
Source: The official website of the State Drug Administration.
Flurbiprofen is a non-steroidal anti-inflammatory and analgesic.
It can be used to reduce or relieve osteoarthritis, frozen shoulder, tendinitis and tenosynovitis, external humeral epicondylitis and trauma.
The swelling and pain
.
At present, flurbiprofen preparations that have been marketed in China include flurbiprofen axetil injection, flurbiprofen gel plaster, flurbiprofen sustained-release tablets and so on
.
According to data from Menet.
com, the market size of terminal flurbiprofen in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) in 2020 will exceed 2 billion yuan, of which plasters account for More than 60%
.
In the competitive landscape of plaster chemical products, flurbiprofen gel plaster ranks first with a market share of nearly 50%
.
Jiudian Pharmaceutical, Sanlian Pharmaceutical, and Wuhan Famaxing submitted applications for the listing of flurbiprofen gel plasters in the category of imitations.
Among them, Jiudian Pharmaceutical's products have entered the administrative examination and approval stage first and become the second domestic manufacturer
.
The source of the newly classified plasters submitted for production and under review: Meinenet MED2.
0 Chinese Drug Evaluation Database Currently no plasters have passed or deemed to have passed the consistency evaluation, flurbiprofen gel plaster, loxoprofen sodium Two types of gel plasters have been reported for production by companies under the new registration classification.
Among them, the flurbiprofen gel plaster of Jiudian Pharmaceutical is expected to become the first plaster to be reviewed
.
Source: Mi Nei.
com database, China National Food and Drug Administration.
.
According to data from Meinnet.
com, flurbiprofen gel plaster will have a terminal sales of more than 1 billion yuan in China's public medical institutions in 2020, making it the best-selling plaster
.
Source: The official website of the State Drug Administration.
Flurbiprofen is a non-steroidal anti-inflammatory and analgesic.
It can be used to reduce or relieve osteoarthritis, frozen shoulder, tendinitis and tenosynovitis, external humeral epicondylitis and trauma.
The swelling and pain
.
At present, flurbiprofen preparations that have been marketed in China include flurbiprofen axetil injection, flurbiprofen gel plaster, flurbiprofen sustained-release tablets and so on
.
According to data from Menet.
com, the market size of terminal flurbiprofen in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) in 2020 will exceed 2 billion yuan, of which plasters account for More than 60%
.
In the competitive landscape of plaster chemical products, flurbiprofen gel plaster ranks first with a market share of nearly 50%
.
Jiudian Pharmaceutical, Sanlian Pharmaceutical, and Wuhan Famaxing submitted applications for the listing of flurbiprofen gel plasters in the category of imitations.
Among them, Jiudian Pharmaceutical's products have entered the administrative examination and approval stage first and become the second domestic manufacturer
.
The source of the newly classified plasters submitted for production and under review: Meinenet MED2.
0 Chinese Drug Evaluation Database Currently no plasters have passed or deemed to have passed the consistency evaluation, flurbiprofen gel plaster, loxoprofen sodium Two types of gel plasters have been reported for production by companies under the new registration classification.
Among them, the flurbiprofen gel plaster of Jiudian Pharmaceutical is expected to become the first plaster to be reviewed
.
Source: Mi Nei.
com database, China National Food and Drug Administration.
